Immuno-Biological Laboratories Balance Sheet Health
Financial Health criteria checks 6/6
Immuno-Biological Laboratories has a total shareholder equity of ¥1.3B and total debt of ¥235.0M, which brings its debt-to-equity ratio to 18.6%. Its total assets and total liabilities are ¥1.6B and ¥353.0M respectively. Immuno-Biological Laboratories's EBIT is ¥110.0M making its interest coverage ratio 110. It has cash and short-term investments of ¥734.0M.
Key information
18.6%
Debt to equity ratio
JP¥235.00m
Debt
| Interest coverage ratio | 110x |
| Cash | JP¥734.00m |
| Equity | JP¥1.27b |
| Total liabilities | JP¥353.00m |
| Total assets | JP¥1.62b |
Financial Position Analysis
Short Term Liabilities: 4570's short term assets (¥1.3B) exceed its short term liabilities (¥257.0M).
Long Term Liabilities: 4570's short term assets (¥1.3B) exceed its long term liabilities (¥96.0M).
Debt to Equity History and Analysis
Debt Level: 4570 has more cash than its total debt.
Reducing Debt: 4570's debt to equity ratio has reduced from 31.3% to 18.6% over the past 5 years.
Debt Coverage: 4570's debt is well covered by operating cash flow (56.6%).
Interest Coverage: 4570's interest payments on its debt are well covered by EBIT (110x coverage).